Current Epidemiology of Pneumocystis Pneumonia
Alison Morris*†
, Jens D. Lundgren‡, Henry Masur§, Peter D. Walzer¶, Debra L. Hanson#, Toni Frederick#, Laurence Huang**, Charles B. Beard††, and Jonathan E. Kaplan#
Author affiliations: *University of Southern California, Los Angeles, California, USA; †University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; ‡University of Copenhagen, Hvidovre, Denmark; §National Institutes of Health, Bethesda, Maryland, USA; ¶University of Cincinnati, Cincinnati, Ohio, USA; #Centers for Disease Control and Prevention, Atlanta, Georgia, USA; **University of California San Francisco, San Francisco, California, USA; ††Centers for Disease Control and Prevention, Fort Collins, Colorado, USA
Main Article
Figure 1
Figure 1. Yearly opportunistic infection rates per 1,000 person-years, CDC Adult and Adolescent Spectrum of Disease Project, 1994–2001 CMV, cytomegalovirus; HAART, highly active antiretroviral therapy; KS, Kaposi sarcoma; MAC, Mycobacterium avium complex; PCP, Pneumocystis pneumonia. Data are standardized to the population of AIDS cases reported nationally in the same year by age, sex, race, HIV exposure mode, country of origin, and CD4+ lymphocyte count.
Main Article
Page created: March 30, 2011
Page updated: March 30, 2011
Page reviewed: March 30, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.